AbbVie 2013 Annual Report Download - page 64

Download and view the complete annual report

Please find page 64 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

AbbVie Inc. and Subsidiaries
Consolidated Statements of Equity
Accumulated
Common Additional other Net parent
years ended December 31 shares Common Treasury paid-in comprehensive Retained company
(in millions) outstanding stock stock capital Income (loss) earnings investment Total
Balance at December 31, 2010 $— $ $ $ 288 $ $ 15,415 $ 15,703
Net earnings 3,433 $ 3,433
Net transactions with Abbott
Laboratories (6,891) $ (6,891)
Other comprehensive loss, net
of tax (313) $ (313)
Balance at December 31, 2011 (25) 11,957 $ 11,932
Net earnings 5,275 $ 5,275
Net transactions with Abbott
Laboratories (13,519) $(13,519)
Assumption of accumulated
unrealized losses on pension
and other post-employment
benefits, net of tax benefit of
$36 (296) $ (296)
Other comprehensive loss, net
of tax (29) $ (29)
Balance at December 31, 2012 (350) 3,713 $ 3,363
Separation-related adjustments (1,316) (662) 707 $ (1,271)
Reclassification of parent
company net investment in
connection with separation 4,420 (4,420) $
Issuance of common stock at
separation 1,577 16 (16) — $
Net earnings 4,128 $ 4,128
Other comprehensive income,
net of tax 570 $ 570
Dividends declared (2,561) $ (2,561)
Share repurchases (4) (223) $ (223)
Stock-based compensation
plans, net of tax benefits of
$(38), and other 14 (97) 583 $ 486
Balance at December 31, 2013 1,587 $16 $(320) $ 3,671 $(442) $ 1,567 $ $ 4,492
The accompanying notes are an integral part of these consolidated financial statements.
60